Therefore, it is highly recommended that information on the presence and degree of DR should be incorporated in the randomization process of patients with DM for any future studies with GLP-1 RAs and SGLT-2 inhibitors, regardless of outcomes the studies are aimed at. The gene discussed is GLP1R; the disease is diabetes mellitus.